Carl Icahn
Carl Icahn's Portfolio
| Ticker | # of Shares | Price | Value | |
|---|---|---|---|---|
| CVI | 71,198,718 | $66.90 | $4,763,194,235 | |
| NFLX | 5,541,066 | $228.56 | $1,266,466,045 | |
| CHK | 59,698,689 | $21.10 | $1,259,642,338 | |
| FRX | 30,662,005 | $37.51 | $1,150,131,808 | |
| RIG | 20,154,035 | $52.31 | $1,054,257,571 | |
| HLF | 16,966,485 | $47.05 | $798,273,120 | |
| HLF | 16,355,131 | $47.05 | $769,508,914 | |
| FDML | 76,697,804 | $9.38 | $719,425,402 | |
| NUAN | 33,899,274 | $19.24 | $652,222,032 | |
| HAIN | 7,239,963 | $67.52 | $488,842,302 | |
| View Additional Portfolio Information » | ||||
Carl Icahn is a billionaire financier, ranking #18 on the 2007 Forbes 400 list with an estimated net worth of $14.5 billion.
Icahn built a name for himself in the 1980s as a corporate raider. After keeping quite for years, Icahn made a major comeback as a 'activist investor'. An activist investor agitates companies for changes, including buyouts, share buybacks, and dividend increases.
Icahn has successfully pushed for changes at Time Warner (NYSE: TWX) and Temple-Inland (NYSE: TIN), among others. Icahn won board seats at Motorola (NYSE: MOT) after first failing.
In 2007, Icahn's activism successfully pushed biotech company MedImmune into a sales agreement with AstraZeneca (NYSE: AZN). Icahn is also involved with biotech company Imclone Systems (Nasdaq: IMCL), where he is Chairman of the Board.
In early, 2008 Icahn activist target BEA Systems (Nasdaq: BEAS) was sold to Oracle (Nasdaq: ORCL). Icahn held a 13% stake in BEA.
Icahn is also involved with developments at Biogen Idec (Nasdaq: BIIB) and WCI Communities (NYSE: WCI), which both unsuccessfully explored sales. WCI rejected a $22 per share takeover offer from Icahn in early 2007, only to see its stock plummet on the housing slowdown.
In 2008, Icahn targeted Yahoo! (Nasdaq: YHOO) after the Internet company failed to work out an acceptable merger agreement with Microsoft (Nasdaq: MSFT) Microsoft walked away from its bid for Yahoo! after months of bickering.
-
Amylin (AMLN) Shares Pop on New M&A Chatter (BMY) (AZN)
-
Icahn Sends Letter to Amylin (AMLN) Board; Says Company Should Be Sold
-
Sanofi-Aventis (SNY) On the Prowl For A Mega-Deal In the U.S.?
-
Like ImClone, Icahn Will Get Amylin (AMLN) Sold
-
Notable Mergers and Acquisitions of the Day 10/06: IMCL/LLY, VSH/IRF, EBAY
-
ImClone (IMCL) Enters Merger Agreement With Eli Lilly (LLY) For $70/Share
-
ImClone's (IMCL) Carl Icahn Issues Statement On Takeover Bid
-
ImClone Systems (IMCL) Chairman Carl Icahn Sends Letter to Bristol-Myers
-
Unusual 11 Mid-Day Movers 9/10: ACBA, AVAV, STLD, RBN Higher; ENCO, DTG, GFIG, WM Lower
-
Analyst Expects Immediate $70/Share Offer for ImClone (IMCL) from Bristol-Myers Following News
-
Notable Mergers and Acquisitions of the Day 9/10: IMCL/BMY, VSH/IRF, MSFT/SRVY
-
ImClone (IMCL) Tells Bristol-Myers (BMY) $60/Sh Offer Is Inadequate; Says $70/Sh Offer On the Table From Another
-
ImClone (IMCL) Said Bristol-Myers' (BMY) Offer Substantially Undervalues The Company
-
StreetInsider.com Top 10 News Items 7/28-8/1: Merrill, ImClone, Biogen/Elan, More...
-
Icahn Has A Happy Day, Racks Up Gains of At Least $350M
-
Biotech Takeover Buzz Hot and Heavy After ImClone Offer (ONXX, OSIP, BIIB, AMLN, XPNT, CYPB, ISPH)
-
Notable Mergers and Acquisitions of the Day 7/31 (IMCL/BMY, GM, GG)
-
Pre-Open Movers 7/31: Imclone (IMCL) Surges On Takeover Offer; Akamai (AKAM) Sinks On Results/Guidance
-
Amylin Pharmaceuticals (AMLN) Could Be One To Watch On ImClone Bid
-
Biogen Idec (BIIB) Could Be One To Watch On ImClone Bid
-
Bristol-Myers (BMY) Offers $60/Share for ImClone (IMCL) In Letter To Icahn
